基于决策树模型的玉屏风胶囊治疗慢性阻塞性肺疾病稳定期的药物经济学评价OA

Objective To evaluate the cost-effectiveness of Yupingfeng Capsules for chronic obstructive pulmonary disease(COPD)patients based on decision tree model.Methods From the perspective of healthcare system,TreeAge Pro 2018.2.1 software was used to build a decision tree model to simulate the total cost and clinical output of Yupingfeng capsule combined with conventional western medicine therapy in the treatment of COPD compared with conventional Western medicine therapy,and incremental analysis and sensitivity analysis were conducted.The cost data came from relevant price websites,and the efficacy data came from meta-analysis.Results Compared with the control group,the incremental cost and incremental effect of Yupingfeng capsule group were 1 069.2 yuan and 1.3 times,respectively,and the incremental cost-effectiveness ratio(ICER)was 822.46 yuan.In other words,when Yupingfeng capsule combined with conventional western medicine was used to treat COPD patients in stable stage,it would cost 822.46 yuan more for each less acute exacerbation.Taking per capita disposable income in 2020(RMB 32 189,National Bureau of Statistics)as the reference standard for basic analysis,ICER accounts for 2.56％ of per capita disposable income.Therefore,under the assumption that the per capita disposable income in 2020 is the patient's willingness to pay threshold,Yupingfeng capsule combined with conventional therapy is more economical than conventional therapy alone.The results of sensitivity analysis show that the results of basic analysis are more robus.Conclusion Yupingfeng capsule combined with conventional western medicine therapy is more economical than conventional Western medicine therapy alone in reducing the number of acute exacerbations.